Trends in cervical cancer in the Netherlands until 2007: Has the bottom been reached?

International Journal of Cancer

Volumn 128, Issue 9, 2011, Pages 2174-2181

  De Kok, Inge M C M ^a   Van Der Aa, Maaike A ^b   Van Ballegooijen, Marjolein ^a   Siesling, Sabine ^b,c   Karim Kos, Henrike E ^a   Van Kemenade, Folkert J ^d   Coebergh, Jan Willem W ^a,e  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Integraal Kankercentrum Noord Nederland   (Netherlands)

^c UNIVERSITY OF TWENTE   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Eindhoven Cancer Registry   (Netherlands)

Author keywords

Cervical cancer; Epidemiology; Incidence; Mortality; Screening; Trend analysis

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORPHOLOGY; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CANCER STAGING; CHILD; FEMALE; HEALTH PROGRAM; HUMAN; INFANT; MAJOR CLINICAL STUDY; NETHERLANDS; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SQUAMOUS CELL CARCINOMA; TREND STUDY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM STAGING; NETHERLANDS; REGISTRIES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 79952462869     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25553     Document Type: Article

References (41)

1. Netherlands Cancer Registry. Incidence and mortality figures cervical cancer. Available at: www.ikcnet.nl, 2007.
2. van der Aa MA, Pukkala E, Coebergh JW, Anttila A, Siesling S. Mass screening programmes and trends in cervical cancer in Finland and the Netherlands. Int J Cancer 2008;122:1854-8. (Pubitemid 351413434)
3. van der Graaf Y, Zielhuis GA, Peer PG, Vooijs PG. The effectiveness of cervical screening: a population-based case-control study. J Clin Epidemiol 1988;41: 21-6. (Pubitemid 18062421)
4. Kalliala I, Dyba T, Nieminen P, Hakulinen T, Anttila A. Mortality in a long-term follow-up after treatment of CIN. Int J Cancer 2010;126:224-31.
5. van der Aa MA, Schutter EM, Looijen- Salamon M, Martens JE, Siesling S. Differences in screening history, tumour characteristics and survival between women with screen-detected versus not screen-detected cervical cancer in the east of the Netherlands, 1992-2001. Eur J Obstet Gynecol Reprod Biol 2008;139:204-9.
6. Giard RW, Hermans J, Doornewaard H. [National results of cervix cytology diagnosis in 1992; efficacy of screening could be improved]. Ned Tijdschr Geneeskd 1994;138:1325-30.
7. van Ballegooijen M, Boer R, van Oortmarssen G, Koopmanschap M, Lubbe J, Habbema J. Cervical cancer screening programme: age ranges and intervals. An updated cost-effectiveness analysis (In Dutch). [Report] Department of Public Health, Erasmus University, 1993.
8. van Ballegooijen M, Habbema JD, van Oortmarssen GJ, Koopmanschap MA, Lubbe JT, van Agt HM. Preventive Papsmears: balancing costs, risks and benefits. Br J Cancer 1992;65:930-3.
9. van Elven E, Griffioen H, Wiegman H. Survey into bottlenecks of the origanised cervical cancer screening programme (In Dutch). [Report] KPMG, 1990.
10. Simons H. Organised cervical cancer screening programme (In Dutch) [Letter of the ministry of Welfare, Public Health and Cultural Affairs, 18 April 1991 (PEP/GZ 001027)], Rijswijk, 1991.
11. National Health Insurance Council, Starting points for the restructuring of the organised cervical cancer screening programme - final decision (In Dutch). Amstelveen, Ziekenfondsraad, 1993.
12. Rebolj M, van Ballegooijen M, Berkers LM, Habbema D. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer 2007;120:806-12. (Pubitemid 46175400)
13. Wheeler CM. Natural history of human papillomavirus infections, cytologic and histologic abnormalities, and cancer. Obstet Gynecol Clin North Am 2008;35:519-36; vii.
14. PALGA. Description of the PALGA system and computer network (in Dutch) Utrecht, The Netherlands, Available at: http:// www.palga.nl, 2004.
15. Fritz A, Perry C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S, eds. International classification of diseases for oncology, 3rd edn. Geneva: WHO, 2000.
16. UICC. TNM classification of malignant tumours, 6th edn. Hoboken, NJ: Wiley, 2002.
17. Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH, Meijer GA. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 2007;29: 19-24. (Pubitemid 46535194)
18. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008;44:1345-89.
19. Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer 2009;45: 2640-8.
20. Bulk S, Visser O, Rozendaal L, Verheijen RH, Meijer CJ. Cervical cancer in the Netherlands 1989-1998: decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer 2005;113:1005-9.
21. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States - a 24-year population-based study. Gynecol Oncol 2000;78:97-105. (Pubitemid 30650338)
22. Rebolj M, van Ballegooijen M, van Kemenade F, Looman C, Boer R, Habbema JD. No increased risk for cervical cancer after a broader definition of a negative Pap smear. Int J Cancer 2008;123:2632-5.
23. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H, Herbert A, von Karsa L. European guidelines for quality assurance in cervical cancer screening. Second edition - summary document. Ann Oncol 2010;21:448-58.
24. van den Akker-van Marle ME, van Ballegooijen M, van Oortmarssen GJ, Boer R, Habbema JD. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst 2002; 94:193-204. (Pubitemid 34162753)
25. van Ballegooijen M. Effects and costs of cervical cancer screening. Department of Public Health Rotterdam (The Netherlands): Erasmus University, 1998.
26. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004;364:249-56. (Pubitemid 38942814)
27. Lynge E, Jensen OM. Cohort trends in incidence of cervical cancer in Denmark in relation to gonorrheal infection. Acta Obstet Gynecol Scand 1985;64:291-6. (Pubitemid 15039845)
28. Laukkanen P, Koskela P, Pukkala E, Dillner J, Laara E, Knekt P, Lehtinen M. Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol 2003;84: 2105-9. (Pubitemid 36927240)
29. Lehtinen M, Kaasila M, Pasanen K, Patama T, Palmroth J, Laukkanen P, Pukkala E, Koskela P. Seroprevalence atlas of infections with oncogenic and nononcogenic human papillomaviruses in Finland in the 1980s and 1990s. Int J Cancer 2006;119:2612-9. (Pubitemid 44691316)
30. Coupe VM, Berkhof J, Bulkmans NW, Snijders PJ, Meijer CJ. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 2008;98:646-51. (Pubitemid 351214513)
31. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RH, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370: 1764-72. (Pubitemid 350137476)
32. de Graaf H, Meijer S, Poelman J, Vanwesenbeeck I. Seks onder je 25e. Seksuele gezondheid van jongeren in Nederland anno 2005ed. Delft: Eburon, 2005.
33. Bakker F, Vanwesenbeeck I. Seksuele gezondheid in Nederland 2006ed. Delft: Eburon, 2006.
34. Karim-Kos HE, Janssen-Heijnen ML, van Iersel CA, van der Meer RM, de Vries E, Coebergh JW. The beginning of the end of the lung cancer epidemic in Dutch women? Int J Cancer 2008;123:1472-5.
35. Statistics Netherlands (CBS). Reported use of medical services and drugs. Available at: www.cbs.nl, 2009.
36. Schouten LJ, van der Does-van den Berg A, Otter R, Coebergh JW. Accuracy and completeness of the registration of childhood leukaemia in The Netherlands, 1989-1992. Eur J Cancer 1997;33:891-4.
37. Liyanage SH, Roberts CA, Rockall AG. MRI and PET scans for primary staging and detection of cervical cancer recurrence. Womens Health (Lond Engl) 2010;6: 251-67; quiz 68-9.
38. van der Aa MA, Siesling S, Kruitwagen RF, Lybeert ML, Coebergh JW, Janssen- Heijnen ML. Comorbidity and age affect treatment policy for cervical cancer: a population-based study in the south of The Netherlands, 1995-2004. Eur J Gynaecol Oncol 2008;29:493-8.
39. van der Aa MA, Siesling S, Louwman MW, Visser O, Pukkala E, Coebergh JW. Geographical relationships between sociodemographic factors and incidence of cervical cancer in the Netherlands 1989-2003. Eur J Cancer Prev 2008;17:453-9.
40. van der Zee J, Gonzalez GD. The Dutch Deep Hyperthermia Trial: results in cervical cancer. Int J Hyperthermia 2002;18: 1-12.
41. van Kemenade FJ, Wiersma T, Helmerhorst TJ. [New version of the pathology practice guideline for cervical cytology: sharpened criteria for adequacy; expanded use of new techniques]. Ned Tijdschr Geneeskd 2007;151:1283-6.